Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 577Carcinoma, Non-Small-Cell Lung 491Ovarian Neoplasms 328Lung Neoplasms 208Fallopian Tube Neoplasms 153Neoplasms 152Stomach Neoplasms 128Esophageal Neoplasms 127Triple Negative Breast Neoplasms 125Neoplasm Metastasis 121Carcinoma, Ovarian Epithelial 115Squamous Cell Carcinoma of Head and Neck 96Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Head and Neck Neoplasms 78Esophageal Squamous Cell Carcinoma 77Adenocarcinoma of Lung 49Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 35Carcinoma, Squamous Cell 34Prostatic Neoplasms 32Pancreatic Neoplasms 30Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER-2 Gene Amplification × Paclitaxel × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡